ResMed Inc. (NYSE:RMD) Shares Acquired by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP boosted its position in ResMed Inc. (NYSE:RMD - Free Report) by 9.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 742,412 shares of the medical equipment provider's stock after purchasing an additional 65,999 shares during the period. Dimensional Fund Advisors LP owned about 0.51% of ResMed worth $169,789,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. OFI Invest Asset Management acquired a new stake in ResMed in the 4th quarter valued at about $39,000. BankPlus Trust Department acquired a new stake in ResMed during the 4th quarter valued at $44,000. Rosenberg Matthew Hamilton acquired a new position in shares of ResMed in the fourth quarter worth $54,000. SBI Securities Co. Ltd. purchased a new stake in shares of ResMed in the fourth quarter valued at $67,000. Finally, Kentucky Trust Co acquired a new stake in shares of ResMed during the fourth quarter valued at $82,000. 54.98% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $242.11, for a total transaction of $484,220.00. Following the transaction, the director now owns 77,218 shares of the company's stock, valued at approximately $18,695,249.98. This trade represents a 2.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Michael J. Farrell sold 8,009 shares of the business's stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $236.77, for a total value of $1,896,290.93. Following the completion of the sale, the chief executive officer now owns 455,472 shares of the company's stock, valued at $107,842,105.44. This trade represents a 1.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 49,013 shares of company stock worth $11,298,816. 0.71% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

RMD has been the subject of a number of analyst reports. The Goldman Sachs Group started coverage on shares of ResMed in a research report on Thursday, January 16th. They issued a "buy" rating for the company. StockNews.com lowered ResMed from a "buy" rating to a "hold" rating in a research note on Thursday. UBS Group cut their price objective on shares of ResMed from $290.00 to $285.00 and set a "buy" rating on the stock in a report on Thursday. JPMorgan Chase & Co. upped their price target on shares of ResMed from $286.00 to $290.00 and gave the stock an "overweight" rating in a research report on Thursday. Finally, Royal Bank of Canada lifted their price target on shares of ResMed from $247.00 to $255.00 and gave the company a "sector perform" rating in a report on Thursday. One analyst has rated the stock with a sell rating, six have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $258.83.

ResMed Stock Down 0.7 %

Shares of NYSE RMD traded down $1.66 during trading on Monday, reaching $234.22. 836,341 shares of the stock were exchanged, compared to its average volume of 1,074,000. The business's 50-day moving average price is $221.92 and its 200 day moving average price is $234.00. The company has a market capitalization of $34.40 billion, a price-to-earnings ratio of 27.65, a price-to-earnings-growth ratio of 1.53 and a beta of 0.75. ResMed Inc. has a twelve month low of $179.42 and a twelve month high of $263.05. The company has a quick ratio of 2.29, a current ratio of 3.33 and a debt-to-equity ratio of 0.13.

ResMed (NYSE:RMD - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $2.37 earnings per share for the quarter, beating analysts' consensus estimates of $2.36 by $0.01. ResMed had a net margin of 25.34% and a return on equity of 26.17%. The company had revenue of $1.29 billion during the quarter, compared to analysts' expectations of $1.28 billion. During the same period in the prior year, the company posted $2.13 EPS. The firm's revenue for the quarter was up 7.9% on a year-over-year basis. As a group, equities analysts forecast that ResMed Inc. will post 9.47 EPS for the current fiscal year.

ResMed Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 12th. Shareholders of record on Thursday, May 8th will be given a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date is Thursday, May 8th. ResMed's payout ratio is 23.79%.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.